Allergan’s Restasis Sales Increase 3.4 Percent in Q1-2017

May 12, 2017: By Joan McKenna

Allergan-logoAllergan’s Restasis sales continued to grow in the US in the first quarter of 2017 despite the market entry of competitor Xiidra in August 2016. CEO Brent Saunders said the company was “back on offense” with two new launches in the dry eye segment: Restasis Multidose Preservative Free (MDPF) and TrueTear, a nasal neurostimulator.

Allergan reported May 9 that Restasis’ net revenues in Q1-2017 totaled to $308.8 million, a 3.4 percent increase over Q1-2016.

Bill Meury, Allergan’s chief commercial officer, told analysts that Restasis had proven “durable” in the face of Xiidra, and the drug maintained a 75 percent share of the dry eye market, with the market itself growing 25 percent over the past year.

Meury said newly approved Restasis MDPF accounted for about a 10 percent share of new Restasis prescriptions after one month of promotion.

And he said TrueTear’s launch is being rolled out in stages now through 2018.

In the US, Allergan’s glaucoma drug franchise saw a modest decline, with Alphagan/Combigan net revenues stable at $86.4 million, while Lumigan/Ganfort net revenues declined 9 percent to $74.3 million.

Ozurdex net revenues in the US were $22.5 million, up 16 percent over Q1-2016, driven by continued strong demand from the diabetic macular edema indication.

Outside the US, Restasis sales declined 7.3 percent to $13.9 million from $15.0 million. Allergan’s Lumigan/Ganfort and Alphagan/Combigan revenues were a stable $85.9 million and $42.3 million, respectively, while Ozurdex revenues were up 29 percent and totaled $51.1 million, excluding foreign exchange impact. Optive revenues outside the US were $27.5 million, up 13 percent, excluding foreign exchange.

Also of note, Allergan said it has completed enrollment of both Phase III studies of abicipar pegol, a long-acting VEGF inhibitor based on DARPin technology, in wet age-related macular degeneration, and the firm expects top line results in 2018.

Allergan reported a Q1-2017 operational loss from continuing operations of $906 million, due in part to amortization and charges related to research and development. The company reduced its debt by $1 billion in Q1-2017, with total debt now standing at about $31.8 billion.

Dublin-based Allergan said its tax rate for the full year is anticipated at about 13 percent.

Allergan’s total net revenues were $3.6 billion, a 5 percent increase over Q1-2016. The company raised its guidance to a range of $15.8 billion to $16 billion, up from previous guidance of $15.5 billion to $15.8 billion range.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Imprimis Offers Compounded Alternative to Restasis for Dry Eye

US District Court Invalidates Four Restasis Patents

BioTime Prices $25 Million Public Offering of Common Stock

Gemini Completes $42.5 Million Series A Financing for Dry AMD Treatment

BIOPHYTIS Raises €10.4 Million to Develop Anti-Aging Drugs, One for Dry AMD

Amydis Receives $530 Thousand NIH Award to Advance Ophthalmic Diagnostic Probes

Realm Announces Completion of $26 million Private Placement

Sight Sciences Secures $10 Million in Oversubscribed Series C Financing

Aerpio Names Stephen Hoffman CEO; Founder Joseph Gardner Remains President

FDA Advisory Panel Recommends Aerie’s Rhopressa for Glaucoma Patients

FDA Panel Unanimously Backs Spark’s Luxturna as Retinal Gene Therapy

PanOptica Secures $11 Million to Advance Topical Anti-VEGF Eye Drop for Neovascular AMD

Nicox and pSivida to Collaborate to Develop a Sustained Release Drug to Lower IOP

Azura Nets $16 Million in Series B Funding for Dry Eye Treatment

Alcon’s AcrySof Intraocular Lens Reaches 100 Million Implants

Notal Vision’s ForeseeHome Reaches Milestone of 3 Million Tests

FDA to Review Spark’s Retinal Gene Therapy Candidate Oct. 12

Alcon’s AutonoMe IOL Injector Gains CE Mark Approval

Shire Sues Allergan, Claiming Bundling Tactics Block Restasis Competitors

Allergan Decries ‘Unfair’ Patent Challenge Process as US House Launches Probe of Tribe Deal

Coming soon

2017 Refractive Surgery Report: A Global Market Analysis for 2016 to 2022